Crispr Therapeutics initiated with a Buy at BTIG. BTIG analyst Amanda Murphy initiated Crispr Therapeutics with a Buy rating and $43 price target. Murphy sees Crispr as a front runner in the allogeneic pack, with its budding CAR-T pipeline. The analyst believes CTX001 represents under 5% of that price target, while the CAR-T franchise represents roughly 35%, and that the largest contribution comes from the value of the company’s underlying platform, which accounts for slightly under 50% of the price target.
https://thefly.com/landingPageNews.php?id=2861455
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.